#1 AI Stock Trading for $3
Sponsored
AI is by far the biggest tech investing trend of 2023. But Ross Givens says the #1 artificial intelligence stock is NOT Microsoft, Google, Amazon or Apple. Nope – his research is pointing to a tiny, under-the-radar stock that's trading for just $3 right now… And could soon shoot to the moon, handing early investors a windfall. This company already has 98 registered patents for cutting-edge voice and sound recognition technology… And has lined up major partnerships with Honda, Netflix, Pandora, Mercedes Benz and many, many others. So if you missed out on Microsoft when it first went public back in 1986… This could be your shot at redemption. Click here now for the full details of this $3 stock that's set to rocket in the AI revolution…
Sponsored by InvestorPlace
Even though AI stocks have done incredibly well in 2023, there remain shares best left alone. Whether you sell in December or earlier, it’s probably best to get rid of these shares quickly.
Some of these stocks have been among the most heavily promoted and strongest-performing firms in 2023. I would argue that all three have failed to meet expectations.
The allure of finding smaller-name AI stocks is clear: Unearthing hidden gems is a lucrative endeavor. Two of the names on this list qualify as smaller AI names. However, I would vehemently discourage investors from considering either of them at this point.
Upstart Holdings (UPST)
Upstart Holdings (NASDAQ:UPST) is among the most dangerous AI stocks available to investors. The company has applied artificial intelligence (AI) to its lending platforms and has gained a lot of attention in doing so. Much of that attention was also negative, judging by the fact that nearly 42% of its float is sold short at present. Thus, a lot of investors are betting that Upstart Holdings will continue to decline.
The reason I’m among their ranks is that I plainly don’t believe in the promises of applying AI to the lending process. It’s a fool’s errand to think an algorithm can accurately assess the multifactorial decision process required. It’s analogous to the situation that happened with home-buying algorithms not long ago. They were touted as a solution that was better than a human-centered approach. However, they couldn’t foresee the increase in rates with any degree of accuracy. As a result, they ended up losing vast sums of money.
AI remains underdeveloped for application to the field of lending. Upstart Holdings’ revenues fell 14% during the most recent period, and its losses were greater than expected. That’s a perfect example of why investors should continue to be skeptical of the company and its promise.
C3.ai (AI)
C3.ai (NYSE:AI) is an enterprise software firm that leverages AI. It was identified as being a leader in that regard. In turn, its stock took off in 2023 on the massive promise of AI applications in the enterprise landscape.
Share prices quadrupled from $11 to $44 in the span of a few months, peaking by early August. Prices have fallen below $30 at present. Like Upstart Holdings, C3.ai is also subject to weak investor sentiment as measured by short selling. Nearly 30% of its float is sold short at the moment.
The reason so many investors are skeptical is because the company continues to disappoint. It posted results in September that heavily contributed to overall skepticism. The company had predicted non-GAAP profitability by the end of the current fiscal year. However, CEO Thomas Siebel recanted that promise upon releasing earnings in early September.
The stock is one of the prime examples of why investors have grown skeptical of AI. Until the company can live up to its profitability promises, it is not worth your money.
Veritone (VERI)
Veritone (NASDAQ:VERI) is the kind of company that promises to be everything to everyone. In the process, it fails to be anything to anyone. It is a generative AI company that believes its services and products apply to all. The company’s mission statement is a dead giveaway. It is littered with words like empowered, democratization and more vibrant opportunities for users of AI everywhere.
It is long on words and short on results. In the third quarter, revenues fell by 6% to $35.1 million. Software revenues make up the bulk of its business accounting for $20.4 million of its revenues during the period. However, software revenues fell by 29% that quarter, which should be particularly troublesome to investors.
That isn’t to say the company hasn’t shown improvement — it has. There have been some bright spots, including strong bookings figures. But overall, the company doesn’t do enough to detract from the negatives. Most importantly, the company’s net loss increased from $4.9 million to $20.9 million year-over-year.
AI Medical Stock Just Received Billions from Big Pharma
Sponsored
Few people know its name, but Intuitive Surgical was one of the five best stocks of the last 20 years.
It went up as much as 18,000% in two decades.
Why?
Because it used new technology – surgical robotics – to drive sales sky high.
Now… another company is following its path.
The company is tiny today – just $500 million – but it is in position to grow dramatically.
In short, it is the inventor of the world's first AI-designed drug to enter clinical trials.
And big pharma is lining up to use its patent-protected technology.
- Merck is collaborating with them on three projects that could generate up to $674 million in revenue.
- French pharma giant Sanofi agreed to pay the company up to $5.2 billion to develop 15 new drugs.
- Bristol Meyers Squibb signed a $1.2 billion partnership with the company.
You can see… each one of these projects is worth more than the entire market cap of this new AI stock!
In short, the upside is MASSIVE.
Which is why I wanted to send you this video.
It comes from one of the great stock pickers of all-time – a man who actually recommended Intuitive Surgical in real time back in 2004.
In fact, he called 4 of the top 6 performing stocks from 2000 to 2020.
And he says this new company is the #1 AI Stock Under $10.
